Dimethylarginine dimethylamino hydrolase-1 (DDAH-1) is an important regulator of nitric oxide (NO) metabolism that has been implicated in the pathogenesis of cardiovascular diseases. Nevertheless, its role in cerebral ischemia still needs to be elucidated. Herein, we examined the expression of DDAH-1 in the brain of rat by double-label immunofluorescence staining. DDAH-1 knock-out (DDAH-1−/−) and wild-type rats underwent middle cerebral artery occlusion/reperfusion (MCAO/R). After 24 h, neurological scores, TTC staining and TUNEL assay were used to evaluate neurological damages. 3 and 7-days infarct outcomes were also shown. Blood-brain-barrier (BBB) permeability was examined via Evans blue extravasation and tight junction (TJ) proteins expression and mRNA levels by western blot and RT-qPCR. The levels of plasma asymmetric dimethylarginine (ADMA), NO and ADMA in brain tissue were also assessed. In addition, supplementation of L-arginine to DDAH-1−/− rats was used to explore its role in regulating NO. DDAH-1 was abundantly distributed in cerebral cortex and basal nuclei, and mainly expressed in neurons and endothelial cells. DDAH-1−/− rats showed aggravated neurological damage and BBB disruption, including decrease of TJ proteins expression but indistinguishable mRNA levels after MCAO/R. DDAH-1 depletion and neurological damages were accompanied with increased ADMA levels and decreased NO concentrations. The supplementation with L-arginine partly restored the neurological damages and BBB disruption. To sum up, DDAH-1 revealed to have a protective role in ischemia stroke (IS) and IS-induced leakage of BBB via decreasing ADMA level and possibly via preventing TJ proteins degradation.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Katan M, Luft A. Global burden of stroke. Semin. Neurol. 2018;38:208–11.
Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, incidence, and mortality of stroke in China. Circulation. 2017;135:759.
Chung JW, Oh MJ, Cho YH, Moon GJ, Kim GM, Chung CS, et al. Distinct roles of endothelial dysfunction and inflammation in intracranial atherosclerotic stroke. Eur. Neurol. 2017;77:211–9.
Na L, Hans W, Milani D, Shufen C, Karin W. Nitric oxide (NO) and asymmetric dimethylarginine (ADMA): their pathophysiological role and involvement in intracerebral hemorrhage. Neurol. Res. 2011;33:541–8.
Patrick V, James L, Blocking NO. synthesis: how, where and why? Nat. Rev. Drug Discov. 2002;1:939–50.
Nadja S, Anja S, Jens ML, Thomas K, Gulistan T, Thomas L, et al. Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cerebrovasc. Dis. 2012;33:37–46.
Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O’Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 2007;13:198–203.
Pope AJ, Karrupiah KP. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production. J. Biol. Chem. 2009;284:35338–47.
Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT–DDAH–ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 2009;60:461–5.
Zhang Y, Fan D, Zhang N. The relationship between serum asymmetric dimethylarginine and ABCD2 score in transient ischemic attack patients. Zhonghua NeiKe ZaZhi. 2014;53:876–9.
Chen S, Li N, Deb-Chatterji M, Dong Q, Kielstein JT, Weissenborn K, et al. Asymmetric dimethyarginine as marker and mediator in ischemic stroke. Int. J. Mol. Sci. 2012;13:15983.
Greco R, Ferrigno A, Demartini C, Zanaboni A, Mangione AS, Blandini F, et al. Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. J. Headache Pain. 2015;16:74.
Molnar T, Pusch G, Nagy L, Keki S, Berki T, Illes Z. Correlation of the L-arginine pathway with thrombo-inflammation may contribute to the outcome of acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 2016;25:2055–60.
Nakayama Y, Ueda S, Yamagishi SI, Obara N, Taguchi K, Ando R, et al. Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int. 2014;85:570–8.
Segarra G, Cortina B, Mauricio MD, Novella S, Lluch P, Navarrete-Navarro J, et al. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. World J. Gastroenterol. 2016;22:10545–56.
Chih-Min T, Hsuan-Chang K, Chien-Ning H, Li-Tung H, You-Lin T. Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. Transl. Res. 2014;164:452–9.
Yokoro M, Nakayama Y, Yamagishi SI, Ando R, Sugiyama M, Ito S, et al. Asymmetric dimethylarginine contributes to the impaired response to erythropoietin in CKD-anemia. J. Am. Soc. Nephrol. 2017;28:2670.
Monti L, Morbidelli L, Bazzani L, Rossi A. Influence of circulating endothelin-1 and asymmetric dimethylarginine on whole brain circulation time in multiple sclerosis. Biomarker Insights. 2017;12:1177271917712514.
Chertow JH, Alkaitis MS, Nardone G, Ikeda AK, Cunnington AJ, Okebe J, et al. Plasmodium infection is associated with impaired hepatic dimethylarginine dimethylaminohydrolase activity and disruption of nitric oxide synthase inhibitor/substrate homeostasis. PLoS Pathog. 2015;11:e1005119.
Donia A, Anne M, Sabine GS, Monique P, Bernard B, Philippe V, et al. Cerebral changes occurring in arginase and dimethylarginine dimethylaminohydrolase (DDAH) in a rat model of sleeping sickness. Plos One. 2011;6:e16891.
Adel B, Oleg P, Ashraf T, Farid H, Ramadan H, Wiebke J, et al. Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. Am J Respir Cell Mol Biol. 2013;49:491–500.
Hu D, Bin W, Hu W, Zhilan L, Jiangtao Y, Xiaojing W, et al. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ. Res. 2010;106:1145–52.
Dê¼Mello R, Sand CA, Pezet S, Leiper JM, Gaurilcikaite E, Mcmahon SB, et al. Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity. Pain. 2015;156:2052–60.
Mookerjee RP, Gautam M, Vairappan B, Mohamed FEZ, Nathan D, Vikram S, et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J. Hepatol. 2015;62:325–31.
Speranza L, Franceschelli S, D’Orazio N, Gaeta R, Bucciarelli T, Felaco M, et al. The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure. Microvasc. Res. 2011;82:391–6.
Bell T, Araujo M, Luo Z, Tomlinson J, Leiper J, Welch WJ, et al. Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine (ADMA) & dimethylarginine dimethylaminohydrolase (DDAH) 1. Am. J. Physiol. Renal Physiol. 2018;315:F74–8.
Shahin NN, Abdelkader NF, Safar MM. A novel role of irbesartan in gastroprotection against indomethacin-induced gastric injury in rats: targeting DDAH/ADMA and EGFR/ERK signaling. Sci Rep. 2018;8:4280.
Frank L, Chi-Un C, Mathias G, Eike-Christin VL, Dorothee A, Edzard S, et al. Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke. Plos One. 2009;4:e7337.
Nannan C, Changhong S, Lu G, Dan Z, Xiufei X, Xiaojun Z, et al. Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 2013;23:465–72.
Haley MJ, Lawrence CB. The blood-brain barrier after stroke: Structural studies and the role of transcytotic vesicles. J. Cereb. Blood Flow Metab. 2016;37:0271678X16629976.
Albert-Weißenberger C, Várrallyay C, Raslan F, Kleinschnitz C, Sirén AL. An experimental protocol for mimicking pathomechanisms of traumatic brain injury in mice. Exp. Transl. Stroke Med. 2012;4:1–5.
Wang D, Li H, Weir E, Xu Y, Xu D, Chen Y. Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats. Int. J. Cardiol. 2019;295:14–20.
Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol. 2007;293:H3227.
Zhao Y, Zhou Y, Ma X, Liu X, Zhao Y, Liu X. DDAH-1 via HIF-1 target genes improves cerebral ischemic tolerance after hypoxic preconditioning and middle cerebral artery occlusion-reperfusion. Nitric Oxide. 2020;95:17–28.
Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke. 2006;37:2024–9.
Czarnecka A, Milewski K, Zielińska M. Asymmetric dimethylarginine and hepatic encephalopathy: cause, effect or association? Neurochem Res. 2017;42:750–61.
Czarnecka A, Aleksandrowicz M, Jasiński K, Jaźwiec R, Kalita K, Hilgier W, et al. Cerebrovascular reactivity and cerebral perfusion of rats with acute liver failure: role of L-glutamine and asymmetric dimethylarginine in L-arginine-induced response. J. Neurochem. 2018;147:692–704.
Behrouzifar S, Vakili A, Bandegi AR, Kokhaei P. Neuroprotective nature of adipokine resistin in the early stages of focal cerebral ischemia in a stroke mouse model. Neurochem. Int. 2018;114:99–107.
Pei Z, Fung PC, Cheung RT. Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J. Pineal Res. 2003;34:110–8.
Hayan D, Rodionov RN, Cynthia L, Cooke JP, Erland A, Teodoro B, et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke. 2008;39:180–4.
Murphy RB, Tommasi S, Lewis BC, Mangoni AA. Inhibitors of the hydrolytic enzyme dimethylarginine dimethylaminohydrolase (DDAH): discovery, synthesis and development. Molecules. 2016;21:615.
Böger RH. L-arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern. Med. Rev. Altern. Med. Rev. 2005;10:14.
Jabecka A, Ast J, Bogdaski P, Drozdowski M, Pawlak-Lemaska K, Cielewicz AR, et al. Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status. Eur. Rev. Med. Pharmacol. Sci. 2012;16:1665–74.
Jiang, X, Andjelkovic, AV, Zhu, L, Yang, T, Bennett, MVL, Chen, J et al. Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog. Neurobiol. 2018;163–4:144–71.
Prakash R, Carmichael ST. Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr. Opin. Neurol. 2015;28:556–64.
Campisi M, Shin Y, Osaki T, Hajal C, Chiono V, Kamm RD. 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes. Biomaterials. 2018;180:117.
Gao W, Li F, Liu L, Xu X, Zhang B, Wu Y, et al. Endothelial colony-forming cell-derived exosomes restore blood-brain barrier continuity in mice subjected to traumatic brain injury. Exp. Neurol. 2018;307:99–108.
Panahpour, H, Farhoudi, M, Omidi, Y & Mahmoudi, J. An in vivo assessment of blood-brain barrier disruption in a rat model of ischemic stroke. J Vis Exp. 2018;133:57156.
Chen FQ, Li Q, Pan CS, Liu YY, Yan L, Sun K, et al. Kudiezi Injection(®) alleviates blood-brain barrier disruption after ischemia-reperfusion in rats. Microcirculation. 2016;23:426–37.
Abdullahi W, Tripathi D, Ronaldson P. Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection. Am. J. Physiol. Cell Physiol. 2018;315:C343–C356.
Ping Z, Xinli H, Xin X, Yingjie C, Bache RJ. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 2011;31:890.
Choi S, Singh I, Singh A, Khan M, Won J. Asymmetric dimethylarginine exacerbates cognitive dysfunction associated with cerebrovascular pathology. FASEB J. 2020;34:6808–23.
Chen Y, Xu X, Sheng M, Zheng Z, Gu Q. Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression. Mol. Vis. 2011;17:332–40.
DDAH-1 knockout SD rats were provided by Professor Da-Chun Xu (Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine).
The present study was supported by the Science and Technology Commission of Shanghai Municipality (grant numbers 18140901900 and 20ZR1443500), National Natural Science Foundation of China (Grant no. 8207052336), and Shanghai Municipal Key Clinical Specialty (Grant no. shslczdzk06102).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhao, Y., Ma, X., Zhou, Y. et al. DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage. Lab Invest (2021). https://doi.org/10.1038/s41374-021-00541-5